Mouse models of Huntington's disease

Trends in Pharmacological Sciences

Volumn 23, Issue 1, 2002, Pages 32-39

  Menalled, Liliana B ^a   Chesselet, Marie Françoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; DICHLOROACETIC ACID; MINOCYCLINE;

AMINO TERMINAL SEQUENCE; DEGENERATIVE DISEASE; DISEASE COURSE; ENZYME SYNTHESIS; EXPERIMENTAL ANIMAL; GENE EXPRESSION; HUMAN; HUNTINGTON CHOREA; KNOCKOUT MOUSE; MITOCHONDRION; MUTATION; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CREATINE; DICHLOROACETATE; ENZYME INHIBITORS; HUMANS; HUNTINGTON DISEASE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MINOCYCLINE; MODELS, ANIMAL; MUTATION; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PROTEINS; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 0036165417     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01884-8     Document Type: Review

References (69)

1. Neuropathological classification of Huntington's disease
2. A novel gene containing a trinucleotide repeat that is unstable on Huntington's Disease chromosomes
3. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies
4. Analysis of a very large trinucleotide repeat in a patient with juvenile Huntington's disease
5. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size
6. Fourteen and counting: Unraveling trinucleotide repeat diseases
7. Inactivation of the mouse Huntington's disease gene homolog Hdh
8. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes
9. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue
10. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion
11. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
12. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
13. Mouse Huntington's disease gene homolog (Hdh)
14. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
15. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
16. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes
17. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
18. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
19. Intranuclear neuronal inclusions: A common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?
20. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain
21. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: Correlation between the density of inclusions and IT15 CAG triplet repeat length
22. Neuronal distribution of intranuclear inclusions in Huntington's disease with adult onset
23. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions
24. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
25. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
26. Mapping the basal ganglia
27. Decrease in striatal enkephalin mRNA in mouse models of Huntington's disease
28. Differential loss of striatal projection neurons in Huntington's disease
29. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis
30. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus
31. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
32. Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's Disease
33. Excitotoxic injury of the neostriatum: A model for Huntington's disease
34. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity
35. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
36. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin
37. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA
38. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration
39. Mouse models of Huntington's disease
40. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice
41. Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice
42. Neurological abnormalities in a knock-in mouse model of Huntington's disease
43. Early motor deficits in CAG repeat knock-in mouse model of Huntington's disease
44. Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
45. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control
46. Dramatic mutation instability in HD mouse striatum: Does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease?
47. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
48. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract
49. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
50. Tissue-specific proteolysis of Huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum
51. Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice
52. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
53. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice
54. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene
55. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
56. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
57. Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease
58. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
59. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease
60. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease
61. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease
62. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease
63. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
64. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain
65. Replicating Huntington's disease phenotype in experimental animals
66. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease
67. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse
68. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation